Table 9.
Indemnity payments (in USD million) for plaintiff verdicts and settlements (adjusted to 2017 USD using the Consumer Price Index)
| Factor | Median (USD million) (IQR) | Difference of medians (USD million) | p valuea |
| Tumor type | |||
| Bone sarcoma | 1.41 (0.45 to 3.33) | 0.62 | 0.51 |
| Soft-tissue sarcoma | 2.03 (0.72 to 4.34) | ||
| Tumor location | |||
| Axial/pelvis | 1.20 (0.39 to 2.94) | 0.75 | 0.44 |
| Extremity | 1.95 (0.67 to 3.41) | ||
| Defendant specialty | |||
| Non-primary care | 1.87 (0.53 to 3.51) | -0.32 | 0.75 |
| Primary care | 1.55 (0.65 to 3.61) | ||
| Non-orthopaedic surgery | 1.87 (0.56 to 3.30) | 0.08 | 0.51 |
| Orthopaedic surgery | 1.95 (0.67 to 4.99) | ||
| Reason for litigation | |||
| Delayed diagnosis without imaging or histologic findings | 1.87 (0.72 to 4.48) | -0.53 | 0.37 |
| Delayed diagnosis with imaging or histologic findings | 1.34 (0.45 to 2.94) | ||
| Injury due to negligence | |||
| No effect on treatment | 1.94 (0.73 to 3.35) | -0.32 | 0.85 |
| Required more extensive treatment (such as surgery, chemotherapy, radiation therapy) | 1.62 (0.47 to 4.24) | ||
| No limb loss | 1.90 (0.62 to 4.10) | -0.03 | 0.88 |
| Limb loss | 1.87 (0.43 to 3.33) | ||
| Localized disease | 1.91 (0.51 to 4.50) | -0.26 | 0.84 |
| Progression to metastatic disease | 1.65 (0.58 to 3.32) | ||
| No death | 1.87 (0.54 to 4.13) | 0.15 | 0.79 |
| Death | 2.02 (0.76 to 3.30) |
a
Mann-Whitney U test; IQR = interquartile range.